$CSII News

Last published 11mo ago

11mo agoSWAV CSIIShockwave Medical, Inc. vs Cardiovascular Systems, Inc. - AIA Trial, Affirmed/Reversed in PartUS Patent Trial and Appeal Board
3y agoAZN CSIIMultidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure - NCT05859048ClinicalTrials.govNumber of participants diagnosed with heart failure (HF) according to the European Society of Cardiology 2021 HF guidelines, Number of outpatient HF visits, Number of urgent HF visit, (and 3 more...)
3y agoABT CSII CTKB SPGICytek Biosciences Set to Join S&P SmallCap 600PR NewswireNEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1.
3y agoCSIICardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical TrialBusiness WireLargest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for
3y agoARGO CSII NUVA OSHMoore Kuehn Encourages ARGO, OSH, CSII, and NUVA Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoARGO CSII NUVA OSHMoore Kuehn Encourages OSH, NUVA, CSII, and ARGO Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 11, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoCSIICSII Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Sale of Cardiovascular Systems, Inc. to Abbott LaboratoriesGlobeNewswireMONSEY, N.Y., Feb. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of Cardiovascular Systems, Inc. (NASDAQ:CSII) ("CSII") acted in the best interests of CSII
3y agoABT CSIICardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial ResultsBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today
3y agoCSIICardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023Business WireCardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00
3y agoCSIICardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical StudyBusiness WireKAIZEN to assess safety and efficacy of peripheral orbital atherectomy to secure regulatory approval in Japan Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing
3y agoCSIICardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.'s Thrombectomy SystemBusiness WireSystem includes mechanical and aspiration thrombectomy devices to treat peripheral vascular disease Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing
4y agoCSIICardiovascular Systems, Inc. to Participate in Two November Healthcare ConferencesBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today
4y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial ResultsBusiness WireConference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of
4y agoCSIICardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy SystemsBusiness WireCardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced
4y agoCSIICardiovascular Systems, Inc. to Host Earnings Conference Call on November 3, 2022Business WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) plans to announce its operating results for the quarter ended September 30, 2022 before the market opens on Thursday, November 3, 2022, and will host a conference
4y agoCSIICardiovascular Systems (CSII) Q4 2022 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending June 30, 2022.
4y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial ResultsBusiness WireWebcast Scheduled for Tomorrow, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET) Revenues of $62.5 million increased 11% sequentially compared to third quarter this year and decreased 12% compared to fourth quarter last year Management provides
4y agoCSIICardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022Business WireWebcast of Capital Markets Day on August 3 will include discussion of fiscal fourth-quarter results Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earning
4y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial ResultsBusiness WireConference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 r
4y agoCSIICardiovascular Systems (CSII) Q3 2022 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending March 31, 2022.
4y agoCSIICardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022Business WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to
4y agoCSIICardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare ConferencesBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to pr
4y agoCSIICardiovascular Systems, Inc. Announces First In-Human Experience With Company's Propel™ Percutaneous Ventricular Assist DeviceBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first in-human experien
4y agoCSIICardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated BalloonBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in
4y agoCSIICardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical OfficerBusiness WireCardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers
4y agoCSIICardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy DevicesBusiness WireMechanical and aspiration devices to treat peripheral vascular disease, deep vein thrombosis and pulmonary embolism Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional
4y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial ResultsBusiness WireConference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure vo
4y agoCSIICardiovascular Systems (CSII) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending December 31, 2021.
4y agoCSIICardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare ConferenceBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to pr
4y agoCSIICardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring BalloonBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today, along with OrbusNeich Medical Compan
4y agoCSIICardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery DiseasesBusiness WireComplementary technology to orbital atherectomy expands CSI's vessel prep market opportunity Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for p
4y agoCSIICardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3Business WireLive Webcast at 8:00 a.m. CT (9:00 a.m. ET) Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will host a live webcast of its fiscal 2022 second-quarter conference call on Thursday, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET). CSI management wi
4y agoCSII SWAVShockwave: Disruption for A Better Fit - NCT05147363ClinicalTrials.govEffectiveness, Major adverse cardiac events, increase in minimum lumen area, (and 3 more...)
4y agoCSIICardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection SystemBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval. CSI has informed all affected healthcare facilities to dis
5y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial ResultsBusiness WireConference Call Scheduled for Today, November 9, 2021, at 8:00 AM CT (9:00 AM ET) Revenues of $58.4 million decreased 3.6% compared to first quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages c
5y agoCSIICardiovascular Systems, inc (CSII) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending September 30, 2021.
5y agoCSIICardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated BalloonBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in
5y agoCSIICardiovascular Systems, Inc. to Participate at the Stifel 2021 Virtual Healthcare ConferenceBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to pr
5y agoCSIICardiovascular Systems, Inc. to Webcast Fiscal 2022 First-Quarter Earnings Conference Call Tuesday, November 9Business WireLive Webcast at 8:00 a.m. CT (9:00 a.m. ET) Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will host a live webcast of its fiscal 2022 first-quarter conference call on Tuesday, November 9, 2021, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will
5y agoCSIICardiovascular Systems, Inc. Announces First Patient Treated with ViperCross™ Peripheral Support CatheterBusiness WireCardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has be
5y agoCSIIFirst Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy SystemBusiness WireIntroduction of Orbital Atherectomy in Canada Expands Treatment Options for Patients with Complex Coronary Artery Disease Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative intervent
5y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial ResultsBusiness WireConference Call Scheduled for Today, August 4, 2021, at 3:30 PM CT (4:30 PM ET) Revenues of $71.0 million increased 66.8% compared to fourth quarter last year and increased 12.2% sequentially compared to third quarter this year Fiscal 2021 reve
5y agoCSIICardiovascular Systems, inc (CSII) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending June 30, 2021.
5y agoCSIICardiovascular Systems, Inc. to Attend Three Investor Conferences in AugustBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to at
5y agoCSIICardiovascular Systems, Inc. to Webcast Fiscal 2021 Fourth-Quarter Earnings Conference Call Wednesday, August 4Business WireLive Webcast at 3:30 p.m. CT (4:30 p.m. ET) Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will host a live webcast of its fiscal 2021 fourth-quarter conference call on Wednesday, August 4, 2021, at 3:30 p.m. CT (4:30 p.m. ET). CSI management wil
5y agoCSIICardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations ConferenceBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to pr
5y agoCSIICardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon CathetersBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the full line of Orbus
5y agoCSIINew Study Demonstrates Exceptional Performance With Cardiovascular Systems' Diamondback 360® Coronary Orbital Atherectomy System (OAS) Dual Mode of ActionBusiness WireCardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-wo
5y agoCSIICardiovascular Systems Inc (CSII) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsCSII earnings call for the period ending March 31, 2021.
5y agoCSIICardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial ResultsBusiness WireConference Call Scheduled for Today, May 6, 2021, at 3:30 PM CT (4:30 PM ET) Revenues of $63.3 million increased 3.4% compared to third quarter last year Net loss of $6.0 million includes $3.4 million related to acquisition of peripheral suppor